<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Fluticasone furoate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08906</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. Despite the similarity in the names,  fluticasone furoate and fluticasone propionate  are different drugs with different properties. It is marketed under the brand name, Veramyst in the US by GlaxoSmithKline for the management of chronic obstructive pulmonary disease (<span class="caps">COPD</span>). <span class="caps">FDA</span> approved on April 27, 2007.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08906/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08906/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08906.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08906.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08906.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08906.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08906.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08906">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Avamys </td><td>GlaxoSmithKline</td></tr><tr><td>Veramyst </td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Breo Ellipta </td><td>Fluticasone furoate and vilanterol </td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/corticosteroids">Corticosteroids</a></li></ul></td></tr><tr><th>CAS number</th><td>397864-44-7</td></tr><tr><th>Weight</th><td>Average: 538.576<br>Monoisotopic: 538.163693965</td></tr><tr><th>Chemical Formula</th><td>C<sub>27</sub>H<sub>29</sub>F<sub>3</sub>O<sub>6</sub>S</td></tr><tr><th>InChI Key</th><td>XTULMSXFIHGYFS-VLSRWLAYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0&#178;,&#8311;.0&#185;&#185;,&#185;&#8309;]heptadeca-3,6-dien-14-yl furan-2-carboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Esters</td></tr><tr><th>Direct parent</th><td>Steroid Esters</td></tr><tr><th>Alternative parents</th><td>Androgens and Derivatives; Hydroxysteroids; Ketosteroids; Halogenated Steroids; Iridoids and Derivatives; Aromatic Monoterpenes; Furoic Acid Derivatives; Cyclohexanols; Thioesters; Ketones; Fluorohydrins; Carboxylic Acid Esters; Cyclic Alcohols and Derivatives; Thiocarboxylic Acid Esters; Dialkyl Ethers; Enolates; Polyamines; Organofluorides; Alkyl Fluorides</td></tr><tr><th>Substituents</th><td>3-keto-steroid; 11-hydroxy-steroid; 9-halo-steroid; 6-halo-steroid; aromatic monoterpene; 11-noriridane monoterpene; monoterpene; furoate; cyclohexanol; cyclic alcohol; carboxylic-thioester; furan; thiocarboxylic acid ester; secondary alcohol; carboxylic acid ester; halohydrin; ketone; fluorohydrin; polyamine; enolate; carboxylic acid derivative; thiocarboxylic acid derivative; ether; dialkyl ether; organofluoride; alcohol; organohalogen; carbonyl group; alkyl halide; alkyl fluoride</td></tr><tr><th>Classification description</th><td>This compound belongs to the steroid esters. These are compounds containing a steroid moeity which bears a carboxylic acid ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Fluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the management of COPD. </td></tr><tr><th>Pharmacodynamics</th><td>Fluticasone furoate binds to human glucocorticoid receptor more potently than dexamethasone (29.9-times) and fluticasone propionate (1.7-times). It also is highly retained in respiratory tissue. The significance of this finding is that fluticasone furoate may have a more pronounced and prolonged anti-inflammatory effect, which allows for once-daily dosing. It does not have any effect on the QTc interval. Furthermore, fluticasone furoate was not found to affect the hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma. </td></tr><tr><th>Mechanism of action</th><td>Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma. </td></tr><tr><th>Absorption</th><td>Following intranasal administration of fluticasone furoate, most of the dose is eventually swallowed and undergoes incomplete absorption and extensive first-pass metabolism in the liver and gut, resulting in negligible systemic exposure. Even at the highest recommended intranasal dose of 110 mcg once daily, plasma concentrations were not quantifiable. This is an especially useful feature as it lowers the incidence of adverse events associated with corticosteroid use. If administered using oral solution and intravenous dosing, 30% of the drug is absorbed and rapidly cleared from the plasma. 
Absolute bioavailability, intranasal route = 0.5%; 
Absolute bioavailability, oral route = 1.26%; 
Mean lung absorption time = 7 hours (regardless of formulation);
</td></tr><tr><th>Volume of distribution</th><td><p>Steady state, IV administration = 608 L</p></td></tr><tr><th>Protein binding</th><td>&gt;99% protein bound. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Fluticasone furoate does not undergo cleavage into its two separate components, fluticasone and the furoate moiety. It undergoes extensive hepatic metabolism via CYP3A4. The principal route of metabolism is hydrolysis of the S-fluoromethyl carbothioate function to form the inactive 17&#946;-carboxylic acid metabolite. Studies suggest that enterocytes may be involved in the metabolism of unabsorbed drug. </p></td></tr><tr><th>Route of elimination</th><td>Fluticasone furoate and its metabolites are eliminated primarily in the feces, accounting for approximately 101% and 90% of the orally and intravenously administered dose, respectively. Urinary excretion accounted for approximately 1% and 2% of the orally and intravenously administered dose, respectively. Fluticasone furoate is extensively metabolized so very little is excreted unchanged. </td></tr><tr><th>Half life</th><td>Elimination phase half-life, IV dose = 15.1 hours;
Elimination phase half-life, inhaled = 17 - 24 hours; </td></tr><tr><th>Clearance</th><td><p>Total plasma clearance = 58.7 L/h</p></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions (&gt;1% incidence) included headache, epistaxis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, and cough. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9917</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9666</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5222</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7675</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.784</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.604</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8329</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8023</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8893</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7205</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6493</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7288</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8305</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6388</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.9211</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.69</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.747
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9079
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6232 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9787
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.566
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Spray, metered</td><td>Nasal</td><td>27.5 mcg/spray</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>